What Roche Middle East does

Roche Middle East is a regional operating subsidiary of F. Hoffmann-La Roche Ltd, the Swiss-headquartered global biotech group (SIX: RO/ROG, OTCQX: RHHBY). Established as the Middle East Management Centre in Dubai in 2012, the entity operates Free Zone branches in Dubai (Roche Pharmaceuticals Middle East FZCO and Roche Diagnostics Middle East FZCO) plus regional centers in Saudi Arabia (Riyadh, Jeddah, Al Khobar), collectively employing approximately 900 people and serving 14-15 countries across the Gulf, Levant, and select South Asian markets. The business operates three divisions: Roche Pharmaceuticals (innovative medicines in oncology, virology, metabolic and CNS disorders, and inflammatory diseases), Roche Diagnostics (in-vitro diagnostics including the Integrated Core Lab automation and digitalization platform), and Roche Diabetes Care (the Accu-Chek portfolio of blood glucose meters, insulin delivery systems, data management platforms, mobile apps including mySugr, and the AI-enabled Accu-Chek SmartGuide CGM launched in October 2025).

The underlying technology spans proprietary diagnostics instruments and reagents, integrated laboratory automation, connected diabetes devices, and predictive AI algorithms on continuous glucose time-series data. Revenue is generated primarily through one-time sales of pharmaceuticals and IVD products to hospitals, laboratories, and government health institutions, supplemented by hardware sales of diabetes devices and recurring subscription-style revenue from digital health applications. Distribution combines direct enterprise field sales through the UAE and KSA headquarters with a network of named local distributors across each country (Pharmatrade in UAE, Ali Abdulwahab Al Mutawa in Kuwait, Ebn Sina Medical in Qatar, National Pharmacy in Oman, Nabil Nabulsi Drugstores in Jordan, Droguerie Omnipharma in Lebanon, and others). Customers span government health authorities, hospitals, laboratories, healthcare professionals, and patients with chronic conditions across oncology, diabetes, cardiovascular disease, and other therapeutic areas. The Jasady (جسدي) registered trademark platform supports patient engagement and disease awareness, and the subsidiary maintains GDPR-compliant data handling via Standard Contractual Clauses.

Name

Roche Middle East

Legal name

Roche Diagnostics Middle East FZCO / Roche Pharmaceutical Middle East FZCO

Website

https://roche-middleeast.com

Company type

Public

Founded year

1896

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Roche Middle East is the Dubai-headquartered regional subsidiary of Swiss biotech group F. Hoffmann-La Roche, serving 14-15 Middle Eastern countries across pharmaceuticals, in-vitro diagnostics, and diabetes care (Accu-Chek), with ~900 employees and an October 2025 AI-enabled CGM launch.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Pharmaceutical products
• In-vitro diagnostics
• Diabetes care solutions
• Continuous glucose monitoring
• Oncology therapies

Headquarters

HQ city

Dubai

HQ country

United Arab Emirates

HQ region

Middle East

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Products: Innovative medicines for cancer, viral infections, metabolic disorders, central nervous system disorders, and inflammatory diseases sold to healthcare providers and institutions
2. In-Vitro Diagnostics: Diagnostic products and solutions including reagents, laboratory equipment, and testing systems sold to hospitals, labs, and healthcare facilities
3. Diabetes Care Products: Blood glucose monitors, insulin delivery systems, and related accessories sold to patients and healthcare providers
4. Digital Health Solutions: Software applications and platforms for diabetes management including mySugr and Accu-Chek SugarView

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Roche Middle East develops and supplies pharmaceutical therapies, in-vitro diagnostics (IVD), and diabetes care solutions for the Middle East region. The company operates through three divisions: Roche Pharmaceuticals (innovative medicines for cancer, viral infections, metabolic disorders, central nervous system, and inflammatory diseases), Roche Diagnostics (IVD solutions for disease detection and clinical decision-making), and Roche Diabetes Care (blood glucose monitoring systems, insulin delivery systems, and digital health solutions including the AI-enabled Accu-Chek SmartGuide CGM).

Product overview

Roche Middle East operates across three main divisions: Roche Pharmaceuticals, Roche Diagnostics, and Roche Diabetes Care. Roche Diabetes Care offers a comprehensive diabetes management ecosystem spanning blood glucose monitoring systems (Accu-Chek Active, Performa, Instant, Guide), insulin delivery systems (Accu-Chek Combo Insulin Pump, Accu-Chek Solo Tubeless Patch Pump, Accu-Fine Pen Needles), data management systems (Accu-Chek SmartPix, Roche Diabetes Care Platform), mobile applications (mySugr Logbook, Accu-Chek SugarView), and the new AI-enabled Accu-Chek SmartGuide CGM. Roche Diagnostics provides In-Vitro Diagnostics solutions for disease detection and patient care. Roche Pharmaceuticals offers innovative medicines for oncology, viral infections, metabolic disorders, CNS disorders, and inflammatory diseases. The Jasady platform serves as a patient engagement initiative connecting diagnostics with patient stories.

Differentiator

Problem solved

Functional benefit

Brands

• Jasady: Arabic-language platform meaning 'my body' that brings real stories to life reflecting the power of diagnostics in understanding bodies and protecting life. Covers diabetes and cardio-metabolic health topics.

Products and services

• Accu-Chek SmartGuide CGM AI-enabled continuous glucose monitoring system providing 14 days of real-time glucose values with predictive notifications up to two hours ahead for adults living with diabetes.
• Accu-Chek Active Blood glucose monitoring system for self-testing by people with diabetes.
• Accu-Chek Performa Blood glucose monitoring system designed for easy and accurate glucose testing.
• Accu-Chek Instant Blood glucose monitoring system offering simple and convenient glucose measurement.
• Accu-Chek Guide Blood glucose monitoring system with enhanced accuracy features.
• Accu-Chek Combo Insulin Pump Insulin pump system combining continuous subcutaneous insulin infusion with glucose monitoring integration.
• Accu-Chek Solo Tubeless Patch Pump Tubeless patch pump for insulin delivery offering discreteness and convenience.
• Accu-Fine Insulin Pen Needles Insulin pen needles for use with insulin pens for subcutaneous insulin injection.
• mySugr Logbook Mobile application for diabetes management allowing users to log blood glucose readings, meals, and activities.
• Accu-Chek SugarView Mobile application for tracking and visualizing glucose data.
• In-Vitro Diagnostics (IVD) Solutions Comprehensive portfolio of in-vitro diagnostic solutions including laboratory tests, diagnostic reagents, and testing systems for disease detection, monitoring, and patient care decisions. Includes Integrated Core Lab (ICL) automation, digitalization, and integration technologies.
• Roche Pharmaceutical Products Innovative pharmaceutical products addressing unmet medical needs in oncology, viral infections, metabolic disorders, central nervous system disorders, and inflammatory diseases.
• Jasady Platform Patient engagement and awareness platform connecting science, diagnostics, and human experience, featuring stories about diabetes and cardiovascular health in the Middle East region.

Quantifiable outcome

• In vitro diagnostics influence over 60% of clinical decision-making while accounting for only about 2% of total healthcare spending
• +3 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Governmental Health Institutions across Middle EastcoreStrategic or Co-development PartnerRoche collaborates with various governmental health institutions across the Middle East to contribute to improving people's health and quality of life through access to innovative medicines and diagnostic solutions.
• Patient and Community OrganizationscoreStrategic or Co-development PartnerRoche partners with patient organizations and community groups to improve healthcare delivery and ensure patients have timely access to new and innovative medicines and diagnostic solutions.
• Leading Healthcare AuthoritiescoreStrategic or Co-development PartnerAs part of social commitment in the Middle East, Roche partners with leading authorities to improve healthcare delivery across the region.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pfizer: Pfizer is a direct peer in oncology, infectious disease, and inflammatory pharmaceuticals across the Middle East and competes for hospital tender business and government formulary listings with Roche Pharmaceuticals.
• Sanofi: Sanofi is a direct peer in diabetes (insulins, Toujeo, Lantus) and specialty pharmaceuticals across the Middle East, and competes with Roche Pharmaceuticals in inflammatory and rare-disease categories.
• Abbott: Abbott is the closest direct peer across all three of Roche Middle East's verticals: pharmaceuticals, in-vitro diagnostics (core lab and point-of-care), and diabetes care, where FreeStyle Libre is the global CGM share leader that Roche's Accu-Chek SmartGuide is positioned against.
• Dexcom: Dexcom is the global CGM technology leader and the most direct functional competitor to the newly launched Accu-Chek SmartGuide CGM across the Middle East.
• Novartis: Novartis is a direct peer in branded innovative pharmaceuticals across oncology, cardiovascular, and CNS therapeutic areas, with overlapping Middle East footprints and competing for the same specialist prescriber base.
• Novo Nordisk: Novo Nordisk is a direct peer in diabetes pharmaceuticals and insulin delivery across the Middle East, and competes head-to-head with Roche Diabetes Care for prescriber relationships and formulary listings on insulins and modern therapies.
• AstraZeneca: AstraZeneca is a direct peer in oncology, cardiovascular, and metabolic pharmaceuticals across the Middle East with established regional offices in the GCC, competing for the same hospital and government accounts as Roche.
• Eli Lilly: Eli Lilly is a direct peer in diabetes (Trulicity, Mounjaro, basal insulins) and oncology across the Middle East, and is rapidly reshaping the diabetes competitive landscape that Roche Diabetes Care serves.
• Johnson & Johnson: Johnson & Johnson is a direct peer across pharmaceuticals (oncology, immunology) and medical devices, with comparable regional Gulf presence and overlapping hospital channel relationships.

Emerging players

• Medtronic: Medtronic competes with Roche Diabetes Care in insulin pumps and is expanding in CGM-adjacent diabetes technology, while also selling IVD-adjacent patient monitoring devices used by the same hospitals as Roche in the Gulf.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/roche
• YouTubeyoutube.com/playlist?list=PLmXzuVn0p6GC84uCtUXTVmmNU8Y7WYFEh
• Facebookfacebook.com/roche/?brand_redir=1317882575008765
• LinkedInlinkedin.com/company/roche-diagnostics-middle-east
• Instagraminstagram.com/roche_middle_east

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Middle East